Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 6/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415414 | 0.78 | GRIN1 (0.40) | MAPTGRIN1GRIN2BKMT2APOLB | |
| SCHEMBL1710683 | 0.77 | KMT2A (0.44) | MAPTKMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL12415632 | 0.75 | MAPT (0.52) | MAPTKMT2APOLBKCNN4ALDH1A1 | |
| SCHEMBL12415413 | 0.74 | GRM5 (0.44) | MAPTKMT2AKCNN4ALDH1A1 | |
| SCHEMBL12415412 | 0.71 | ALDH1A1 (0.41) | KMT2APOLBALDH1A1 | |
| SCHEMBL12415411 | 0.68 | HTT (0.41) | — | |
| SCHEMBL2187144 | 0.68 | LMNA (0.50) | MAPTKMT2APOLBALDH1A1 | |
| SCHEMBL2190524 | 0.67 | CYP3A4 (0.45) | MAPTGRIN1GRIN2BKMT2APOLB | |
| SCHEMBL2189164 | 0.67 | CYP3A4 (0.46) | ALDH1A1 | |
| SCHEMBL18997025 | 0.67 | KMT2A (0.52) | MAPTKMT2APOLBKCNN4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | MAPT 443/4885GRIN1 260/4885GRIN2B 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.